Next Article in Journal
Plasma miRNAs as Biomarkers to Identify Patients with Castration-Resistant Metastatic Prostate Cancer
Next Article in Special Issue
The Importance of the PI3K/AKT/MTOR Pathway in the Progression of Ovarian Cancer
Previous Article in Journal
Sphingomyelin in High-Density Lipoproteins: Structural Role and Biological Function
Previous Article in Special Issue
Regulation of Ovarian Cancer Stem Cells or Tumor-Initiating Cells
Open AccessReview

Aberrant Lipid Metabolism: An Emerging Diagnostic and Therapeutic Target in Ovarian Cancer

1
Discipline of Obstetrics and Gynaecology, School of Paediatrics and Reproductive Health, Research Centre for Reproductive Health, Robinson Institute, University of Adelaide, Adelaide 5005, Australia
2
Genetics and Molecular Pathology, SA Pathology, Women's and Children's Hospital, Adelaide 5006, Australia
3
Department of Gynaecological Oncology, Royal Adelaide Hospital, Adelaide 5000, Australia
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2013, 14(4), 7742-7756; https://doi.org/10.3390/ijms14047742
Received: 1 February 2013 / Revised: 6 March 2013 / Accepted: 7 March 2013 / Published: 10 April 2013
(This article belongs to the Special Issue Genes and Pathways in the Pathogenesis of Ovarian Cancer)
Ovarian cancer remains the most lethal gynaecological cancer. A better understanding of the molecular pathogenesis of ovarian cancer is of critical importance to develop early detection tests and identify new therapeutic targets that would increase survival. Cancer cells depend on de novo lipid synthesis for the generation of fatty acids to meet the energy requirements for increased tumour growth. There is increasing evidence that lipid metabolism is deregulated in cancers, including ovarian cancer. The increased expression and activity of lipogenic enzymes is largely responsible for increased lipid synthesis, which is regulated by metabolic and oncogenic signalling pathways. This article reviews the latest knowledge on lipid metabolism and the alterations in the expression of lipogenic enzymes and downstream signalling pathways in ovarian cancer. Current developments for exploiting lipids as biomarkers for the detection of early stage ovarian cancer and therapeutic targets are discussed. Current research targeting lipogenic enzymes and lipids to increase the cytotoxicity of chemotherapy drugs is also highlighted. View Full-Text
Keywords: ovarian cancer; lipid synthesis; signalling pathways; biomarkers; therapeutic targets ovarian cancer; lipid synthesis; signalling pathways; biomarkers; therapeutic targets
MDPI and ACS Style

Pyragius, C.E.; Fuller, M.; Ricciardelli, C.; Oehler, M.K. Aberrant Lipid Metabolism: An Emerging Diagnostic and Therapeutic Target in Ovarian Cancer. Int. J. Mol. Sci. 2013, 14, 7742-7756. https://doi.org/10.3390/ijms14047742

AMA Style

Pyragius CE, Fuller M, Ricciardelli C, Oehler MK. Aberrant Lipid Metabolism: An Emerging Diagnostic and Therapeutic Target in Ovarian Cancer. International Journal of Molecular Sciences. 2013; 14(4):7742-7756. https://doi.org/10.3390/ijms14047742

Chicago/Turabian Style

Pyragius, Carmen E.; Fuller, Maria; Ricciardelli, Carmela; Oehler, Martin K. 2013. "Aberrant Lipid Metabolism: An Emerging Diagnostic and Therapeutic Target in Ovarian Cancer" Int. J. Mol. Sci. 14, no. 4: 7742-7756. https://doi.org/10.3390/ijms14047742

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Search more from Scilit
 
Search
Back to TopTop